Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: Secondary analysis of the Euro-Ewing99-R1 trial.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Abstract

Based on the randomised Euro-EWING99-R1 trial, vincristine, adriamycin, cyclophosphamide (VAC) may be able to replace vincristine, adriamycin, ifosfamide (VAI) in the treatment of standard-risk Ewing sarcoma. However some heterogeneity of treatment effect by gender was observed. The current exploratory study aimed at investigating the influence of gender on treatment efficacy and acute toxicity.

Detaljer

Författare
  • Henk van den Berg
  • Michael Paulussen
  • Gwénaël Le Teuff
  • Ian Judson
  • Hans Gelderblom
  • Uta Dirksen
  • Bernadette Brennan
  • Jeremy Whelan
  • Ruth Lydia Ladenstein
  • Perrine Marec-Berard
  • Jarmila Kruseova
  • Lars Hjorth
  • Thomas Kühne
  • Benedicte Brichard
  • Keith Wheatley
  • Alan Craft
  • Heribert Juergens
  • Nathalie Gaspar
  • Marie-Cécile Le Deley
Enheter & grupper
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Cancer och onkologi
Originalspråkengelska
Sidor (från-till)2453-2464
TidskriftEuropean Journal of Cancer
Volym51
Utgivningsnummer16
StatusPublished - 2015
PublikationskategoriForskning
Peer review utfördJa